Preface

Four true sentences

A peptide is a short chain of amino acids. That is the whole definition, and it is almost useless.

Consider four statements, all of them true at the same moment:

Insulin is a peptide, and it has kept people alive since 1922. It is arguably the most consequential molecule in the history of pharmacology, and the evidence for it is a century deep.

Semaglutide is a peptide, and it is the most important metabolic drug in fifty years. In a large randomized trial, it reduced cardiovascular events in people who did not have diabetes — a result nobody would have predicted from a molecule originally developed to lower blood sugar.

BPC-157 is a peptide, and as of this writing there is not one completed, peer-reviewed, randomized human trial of it in the published literature. Not one. It is nonetheless one of the most discussed compounds in the self-optimization world, sold openly online, and injected by a great many people who believe the animal data settles the question. It does not.

Oxytocin is a peptide, and the phrase "oxytocin is the love hormone" has probably done more damage to the public understanding of neuroscience than any other five words. Oxytocin does influence social behavior. It also increases in-group favoritism and, in some experimental settings, hostility toward outsiders. The nickname captured a third of the truth and buried the rest.

Four peptides. Four wildly different evidentiary situations. And nothing about the word peptide tells you which is which.

That is the problem this book exists to solve.

Why the public conversation about peptides is such a mess

In 2023, a peptide became the most talked-about drug in the world. Semaglutide — sold as Ozempic for diabetes and Wegovy for weight management — did something drugs almost never do: it worked dramatically, visibly, and on a condition that had defeated pharmacology for decades. Then it kept working on other things. Cardiovascular events. Kidney disease. Possibly liver disease. Possibly addiction. The story was enormous and it was, unusually, mostly true.

And in its wake came everything else.

Because here is what happened next. A public that had never thought about peptides suddenly learned the word. Search traffic exploded. And what people found when they searched was not a coherent field — it was a collision of at least five separate worlds that happen to share a vocabulary:

• Legitimate pharmaceutical science, where GLP-1 receptor agonists have some of the best clinical evidence in modern medicine, built over twenty years and tens of thousands of trial participants.
• Established clinical medicine, where more than eighty peptide drugs are already approved and quietly in daily use — for osteoporosis, for neuroendocrine tumors, for bleeding disorders, for prostate cancer, for diabetes insipidus — and almost nobody outside those specialties knows it.
• Biohacker speculation, where compounds with genuinely interesting animal data and no human trials are discussed with a confidence the evidence cannot possibly support.
• A gray market, where "research peptides — not for human consumption" is a legal fiction everyone understands, quality is unverifiable, and no one is monitoring what happens next.
• Frontier science, where peptide cancer vaccines, antimicrobial peptides, and radioligand therapy are doing real, careful, early work that deserves neither hype nor dismissal.

No single resource untangles these. The scientific literature is scattered across endocrinology, pharmacology, immunology, dermatology, oncology, and biochemistry journals that do not talk to each other. The popular coverage oscillates between miracle and menace with almost nothing in between. The forums have real expertise and real nonsense in the same thread, indistinguishable to a newcomer. And a substantial fraction of the accessible information was written by someone with something to sell.

What this book does differently

Every peptide gets a rating, and every rating gets a reason.

Not a vibe. Not a lean. A four-tier rating — ✅ strong clinical evidence, ⚠️ promising but preliminary, ❌ hype outpaces evidence, 🔬 frontier — attached to a specific claim for a specific population, with the single reason it earned that tier and the specific finding that would change it.

That last part matters more than it looks. A verdict you cannot imagine revising is not a scientific judgment; it is a belief. Every rating in this book comes with its own escape hatch: here is what would have to happen for me to be wrong.

Ratings attach to claims, never to molecules. Semaglutide for weight loss in obesity is ✅. Semaglutide for Alzheimer's disease is 🔬. Those are two ratings for one molecule, and the difference between them is the difference between a completed trial program and a hypothesis being properly tested. A book that gave semaglutide a single rating would be lying by compression.

The book is neither pro-peptide nor anti-peptide. Insulin gets the ✅ that a century of evidence demands. Semaglutide gets the ✅ that its trial program demands. BPC-157 gets ❌ — and the chapter on it takes the rodent literature entirely seriously, describes what is genuinely impressive about it, and explains exactly why that does not settle the human question. Growth hormone gets ✅ for the deficiencies it treats and ❌ for the anti-aging claims built on a twelve-person study from 1990.

Being willing to rate against the reader's expectation in both directions is the only thing that makes any of the ratings worth reading.

And the book teaches the method, not just the verdicts.

Chapter 5 is the most important chapter here, and it contains almost no peptides. It teaches how to read a study: what randomization buys you, why a surrogate endpoint can make a useless drug look good, why "20% reduction in cardiovascular events" and "1.5 percentage points over three years" describe the same result, why one trial can honestly report two different weight-loss numbers, and how to tell in thirty seconds whether a source is worth another thirty seconds.

That skill is the actual deliverable. Peptides are the subject; evidence evaluation is the curriculum. The reader who finishes this book will be able to evaluate a peptide invented after it was published — and, more usefully, a health claim that has nothing to do with peptides at all.

What this book will not do

It will not tell you what to take. Not once. There is no dosing information in these pages, no preparation or reconstitution procedure, no injection technique, no cycle, no protocol, and no vendor. That is a design constraint, enforced by the project's build validator, which flags any sentence that reads like an instruction sheet.

This is not squeamishness. It is a judgment about what a book can and cannot responsibly do. A book does not know your history, cannot order your labs, cannot see the interaction with the medication you did not mention, and is not there at two in the morning when something goes wrong. A clinician can be all four. Chapter 39 is entirely about making that conversation productive, because for many readers the most valuable thing this book can produce is a better appointment.

It will not moralize. A meaningful share of this book's readers already have a vial in the refrigerator. They are not stupid and they are usually not reckless. They are people who wanted help — with weight, with pain, with an injury that would not heal, with aging, with feeling like themselves again — and found a literature that is genuinely hard to read.

You will be given the state of the evidence, the honest unknowns, and the questions worth asking. You will not be lectured. A reader who feels judged closes the book, and a reader who closes the book goes back to the forum, where nobody is going to mention the endotoxin problem.

And it will not pretend to more certainty than exists. The sentence "as of this writing, this has not been established in humans" appears many times in this book. It is not a hedge. It is, frequently, the single most accurate and most useful thing that can be said.

The three tiers of sourcing

Because a book about evidence quality must be transparent about its own, every source in this book is placed in one of three tiers, and the bibliography is organized by them.

Tier 1 — Verified canonical. Things we are confident exist and can stand behind: the chemistry of amino acids and the peptide bond; the FDA, EMA, and WADA as institutions and their published frameworks; named landmark trial programs; approved drugs and their approved indications; the discovery of insulin in Toronto in 1921–22; Merrifield and solid-phase synthesis; du Vigneaud and the first synthesis of a peptide hormone; the phage display work recognized in 2018.

Tier 2 — Attributed, specifics unverified. Real findings whose exact citation we have not pinned down, given as ranges rather than false precision. Most numbers in this book are Tier 2, and that is deliberate. A range you can trust beats a decimal you cannot.

Tier 3 — Illustrative and constructed. Teaching examples built for this book — every constructed study vignette, every worked dossier entry, the four vials on the bench in Chapter 6. Always labeled where it appears, never presented as a real publication.

Nothing in this book is fabricated and presented as real. No invented p-values, no invented trial names, no invented citations, no invented approval dates. In a book about evaluating evidence, a single made-up statistic would be disqualifying — and would deserve to be.

The one thing to carry out of here

The peptide revolution is real. GLP-1 receptor agonists are among the most important drug discoveries of the twenty-first century, peptide therapeutics are advancing quickly, and the molecules themselves are genuinely beautiful things — thirty amino acids in a row, reorganizing global metabolic medicine.

And the hype is also real. Most of the peptides people are most excited about have no human clinical evidence at all, are sold by companies with no obligation to put in the vial what the label claims, and are discussed with a certainty that the underlying science would find embarrassing.

Both of those sentences are true simultaneously. Holding them together — without collapsing into either evangelism or contempt — is the entire skill. It is harder than it sounds, it is the most useful thing this book has to give you, and it transfers to every health claim you will meet for the rest of your life.

Let's start with what a peptide actually is.